FDA Clears Masimo smartSET AI Pulse Oximetry Platform on Radius VSM With 97 Percent AFib Sensitivity

California medical technology developer Masimo announced U.S. Food and Drug Administration (FDA) 510(k) clearance on Sunday, October 18, for atrial fibrillation (AFib) detection on its wearable Radius VSM vital-signs monitor, expanding its AI-enabled smartSET pulse oximetry platform. Hospital cardiology departments, nursing quality boards, and healthcare district officials across Walnut Creek, San Francisco, San Ramon, and Pleasanton welcomed the regulatory clearance as health systems upgrade continuous bedside telemetry. By running advanced waveform analysis directly on existing pulse oximetry sensors, hospitals can screen patients without adding bulky chest leads.

In clinical validation testing submitted to federal regulators, the smartSET AFib pattern-recognition algorithm demonstrated 97 percent sensitivity and 100 percent specificity in identifying irregular cardiac rhythms. The capability targets a common cardiac arrhythmia that affects more than 10 percent of adults over age 65 and frequently goes undiagnosed during routine medical or surgical hospital stays. Cardiology committee directors noted that catching silent paroxysmal AFib early helps physicians initiate stroke-prevention programs and save thousands of dollars per patient in emergency readmissions.

Crucially for hospital workflow efficiency, the newly cleared AFib module integrates alongside Masimo's previously cleared AI-enabled opioid-induced respiratory depression (OIRD) detection capability on the exact same continuous pulse oximetry sensor workflow. Clinical studies show that 1 in 10 (10 percent) surgical patients receiving postoperative opioids experience an opioid-related adverse event. Furthermore, 85 percent of OIRD episodes occur within the first 24 hours after surgery, making unified bedside AI waveform monitoring a top safety priority for California hospital networks.

Biomedical engineering officials and county health department advisors across Contra Costa and Alameda counties emphasized that combining cardiac and respiratory AI alerts on one wearable Radius VSM module reduces alarm fatigue for floor nurses. Hospital procurement boards estimate that deploying multi-parameter wearable monitors across general care wards costs approximately $1,200 per bed while significantly improving postoperative recovery oversight. Regional nursing councils in Walnut Creek and Oakland plan to evaluate the integrated smartSET software during fourth-quarter clinical technology trials.

Healthcare administrators, cardiologists, and clinical engineers can review the FDA 510(k) summary and smartSET validation studies online at masimo.com. Questions regarding regional hospital telemetry evaluations in the East Bay may be directed to clinical engineering staff along Ygnacio Valley Road in Walnut Creek at (925) 939-3000 between 8:00 AM and 5:00 PM Monday through Friday. Additional medical device safety updates are published at fda.gov.